Results 61 to 70 of about 8,852,069 (358)

A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer

npj Precision Oncology
Brigatinib-based therapy was effective against osimertinib-resistant EGFR C797S mutants and is undergoing clinical studies. However, tumor relapse suggests additional resistance mutations might emerge.
Mai Suzuki, Ken Uchibori, Tomoko Oh-hara, Yumi Nomura, Ryusei Suzuki, Ai Takemoto, Mitsugu Araki, Shigeyuki Matsumoto, Yukari Sagae, Mutsuko Kukimoto-Niino, Yusuke Kawase, Mikako Shirouzu, Yasushi Okuno, Makoto Nishio, Naoya Fujita, Ryohei Katayama   +15 more
doaj   +1 more source

Parent‐to‐Child Information Disclosure in Pediatric Oncology

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Despite professional consensus regarding the importance of open communication with pediatric cancer patients about their disease, actual practice patterns of disclosure are understudied. Extant literature suggests a significant proportion of children are not told about their diagnosis/prognosis, which is purported to negatively ...
Rachel A. Kentor, Flora Hoodin, Michelle Byrd, Kristin A. Kullgren, Leah LaLonde, Lauren Benkoske, Patrick Smith, Dawn Carson, Karen MacDonald, Susumu Inoue, Brenda Kitchen, Kate Gowans, Gregory A. Yanik   +12 more
wiley   +1 more source

Autophagy-deficient breast cancer shows early tumor recurrence and escape from dormancy [PDF]

, 2018
Breast cancer patients who initially respond to cancer therapies often succumb to distant recurrence of the disease. It is not clear why people with the same type of breast cancer respond to treatments differently; some escape from dormancy and relapse ...
Manjili, Masoud H.
core   +1 more source

Weekly versus three weeks chemotherapy for advanced ovarian cancer. A meta-analysis [PDF]

, 2016
Aim: Three weeks paclitaxel and carboplatin has been considered the standard of care for primary treatment of ovarian cancer (OC). Whether weekly therapy will further improve the clinical outcomes or not is still unclear.
De Felice, Francesca, Marchetti, Claudia, Monti, Marco, Musella, Angela, Musio, Daniela, Muzii, Ludovico, Palaia, Innocenza, Panici, Pierluigi Benedetti, Tombolini, Vincenzo   +8 more
core   +1 more source

Separation of phosphatidyl ethanolamine, phosphatidyl serine, and other phospholipids by thin-layer chromatography*

Journal of Lipid Research, 1962
Thin-layer chromatography of phospholipids and cerebrosides was performed on Silica Gel G plates using a mixture of chloroform-methanol-acetic acid-water as development solvent.
Vladimir P. Skipski, Robert F. Peterson, Marion Barclay   +2 more
doaj   +1 more source

Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab

BMC Cancer, 2021
Background Giant cell tumor of bone (GCTB) is a rare osteoclastogenic stromal tumor. GCTB can rarely undergo malignant transformation. This post hoc analysis evaluated and classified malignancies in patients with GCTB who received denosumab. Methods This
Emanuela Palmerini, Leanne L. Seeger, Marco Gambarotti, Alberto Righi, Peter Reichardt, Susan Bukata, Jean-Yves Blay, Tian Dai, Danielle Jandial, Piero Picci   +9 more
doaj   +1 more source

Prolonged Corrected QT Interval as an Early Electrocardiographic Marker of Cyclophosphamide‐Induced Cardiotoxicity in Pediatric Hematology and Oncology Patients

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Cyclophosphamide (CY) is associated with potentially fatal cardiotoxicity, yet no electrocardiographic indices have been established for early detection of CY‐induced cardiomyopathy. This study aimed to determine whether corrected QT interval (QTc) prolongation can predict early onset of CY‐related cardiac dysfunction in pediatric ...
Junpei Kawamura, Kentaro Ueno, Takuro Nishikawa, Yoshihiro Takahashi, Koji Nakae, Yasuhiro Okamoto   +5 more
wiley   +1 more source

Developmental Disorders in Children Recently Diagnosed With Cancer

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Neurocognitive deficits in adult survivors of childhood cancer are well established, but less is known about developmental disorders (DD) arising shortly after cancer diagnosis. Using 2016–2019 linked Ohio cancer registry and Medicaid data, we compared DD among 324 children with cancer and 606,913 cancer‐free controls.
Jamie Shoag, Long Vu, Ritika Miryala, Jeffrey M. Albert, Molly McVoy, Siran M. Koroukian   +5 more
wiley   +1 more source

Biomarkers of aging associated with past treatments in breast cancer survivors. [PDF]

, 2017
Radiation and chemotherapy are effective treatments for cancer, but are also toxic to healthy cells. Little is known about whether prior exposure to these treatments is related to markers of cellular aging years later in breast cancer survivors.
Bower, Julienne E, Breen, Elizabeth C, Carroll, Judith E, Chapman, Aaron M, Esquivel, Stephanie, Ganz, Patricia A, Hogan, Matt, Irwin, Michael R, Petersen, Laura, Ramos-Perlberg, Sam, Schiestl, Robert, Scuric, Zorica   +11 more
core   +2 more sources

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistanceResearch in context

EBioMedicine, 2019
Background: Alectinib has shown a greater efficacy to ALK-rearranged non-small-cell lung cancers in first-line setting; however, most patients relapse due to acquired resistance, such as secondary mutations in ALK including I1171N and G1202R.
Koutaroh Okada, Mitsugu Araki, Takuya Sakashita, Biao Ma, Ryo Kanada, Noriko Yanagitani, Atsushi Horiike, Sumie Koike, Tomoko Oh-hara, Kana Watanabe, Keiichi Tamai, Makoto Maemondo, Makoto Nishio, Takeshi Ishikawa, Yasushi Okuno, Naoya Fujita, Ryohei Katayama   +16 more
doaj   +1 more source